Form 8-K Neoleukin Therapeutics, For: Nov 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Stifel Downgrades Neoleukin Therapeutics (NLTX) to Hold
November 15, 2022 4:58 AM ESTStifel analyst Benjamin Burnett downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $0.90 (from $14.00).
The analyst comments "We are downgrading shares to Hold following managements decision to discontinue development of lead asset NL-201 (next-gen IL-2 analogue). Management... More
